## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($192.51)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector**
- Source: Finviz | 20251211T130823 | Bullish | Relevance: 100%
- Morgan Stanley analyst Patrick Wood maintained an Overweight rating on Becton, Dickinson and Company (BDX) and raised the price target to $210, citing a positive outlook for the MedTech sector. The company's MedTech division, New BD, is expected to complete its merger with Waters Corporation by Q1 2026, and BDX reported strong Q4 2025 revenues and cash flow, along with significant returns to shareholders.

**2. Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector**
- Source: Insider Monkey | 20251211T072005 | Bullish | Relevance: 100%
- Morgan Stanley analyst Patrick Wood increased the price target for Becton, Dickinson and Company (BDX) to $210 from $197, maintaining an Overweight rating due to a positive outlook for the MedTech sector. The analyst cited major product cycles, healthier hospital spending, and low valuations as supporting factors for the industry. BDX reported strong fiscal Q4 2025 revenues of $5.9 billion, an 8.3% YoY growth, and plans to complete the merger of its Biosciences and Diagnostic Solutions (New BD) with Waters Corporation by Q1 2026.

**3. Reynders McVeigh Capital Management LLC Has $14.57 Million Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251215T124405 | Somewhat-Bearish | Relevance: 100%
- Reynders McVeigh Capital Management LLC reduced its stake in Becton, Dickinson and Company (BDX) by 12.4%, now holding 84,609 shares valued at $14.57 million. The company recently increased its quarterly dividend to $1.05 per share, and the stock currently holds an average "Hold" rating from analysts with a consensus target of $204.91. Insider selling activity was also reported, with Director Bertram L. Scott selling 217 shares.

**4. Becton Dickinson may sell 60 acres for affordable housing. What we know**
- Source: Bergen Record | 20251215T091944 | Neutral | Relevance: 100%
- The Hekemian Group has reached an agreement to acquire 60 acres of Becton Dickinson's Franklin Lakes campus for affordable housing. This development comes as the borough faces ongoing negotiations and challenges regarding its affordable housing obligations and is one of 16 towns warned about non-compliance. The proposed sale does not include the main part of Becton Dickinson's headquarters.

**5. Lazard Asset Management LLC Acquires 654,930 Shares of Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251214T134749 | Bullish | Relevance: 100%
- Lazard Asset Management LLC significantly increased its stake in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, purchasing an additional 654,930 shares, bringing its total holdings to 760,995 shares valued at approximately $131.1 million. The article also details Becton, Dickinson's recent financial performance, including a quarterly dividend increase to $1.05 per share, and current analyst ratings which maintain a consensus "Hold" with a target price of $204.91. Insider trading activity and other institutional investor movements are also highlighted.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +6.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $57.6B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 12.6 |
| Current P/E | 13.4 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.1% to 3.6% (+6.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.4pp (needs >4.0% for momentum thesis). MRS_5 at 4.1% confirms short-term momentum alignment. AM_20 at 4.0% shows strong absolute momentum above own 20MA. Outperforming sector by 3.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.68), confirming momentum. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.61% (CS: 66) | Neutral |
| RSI_14 | 65.1 | Neutral |
| MACD Histogram | 0.68 | Bullish |
| vs SMA20 | 1.039x | Above |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 1.055x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $200.89
- **Stop Loss:** $192.51 (4.2% risk)
- **Target:** $217.65 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 119
- **Position Value:** $23,905.91
- **Portfolio %:** 23.91%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*